Tanenbaum L, Anderson C, Rosenberg M J, Akers W
Arch Dermatol. 1984 Feb;120(2):216-9.
Sulconazole nitrate, a new imidazole derivative, was formulated at 1% concentration in a cream vehicle and compared with 2% miconazole nitrate cream in the treatment of tinea versicolor in a double-blind, multicenter, randomized, parallel clinical trial. At baseline, all of the 192 patients enrolled had a positive potassium hydroxide (KOH) preparation; itching was reported by 48% of the patients. The medications were applied twice daily for three weeks. Of 181 patients analyzed for efficacy at the end of the treatment trial, 93% of sulconazole-treated patients and 87% of miconazole-treated patients had become KOH negative. The complete clearing of tinea versicolor lesions occurred in 89% of sulconazole-treated patients and 82% of miconazole-treated patients. Both drugs were well tolerated with no systemic reactions reported. Drug-related adverse cutaneous reactions, predominantly transient itching, were reported in eight patients receiving sulconazole and in four patients receiving miconazole.
新型咪唑衍生物硝酸硫康唑以1%的浓度制成乳膏剂,并在一项双盲、多中心、随机、平行的临床试验中,与2%硝酸咪康唑乳膏用于治疗花斑糠疹进行比较。基线时,纳入的192例患者氢氧化钾(KOH)制剂检查均呈阳性;48%的患者有瘙痒症状。药物每日外用两次,共三周。在治疗试验结束时分析疗效的181例患者中,硝酸硫康唑治疗组93%的患者KOH检查转为阴性,硝酸咪康唑治疗组为87%。花斑糠疹皮损完全消退的比例,硝酸硫康唑治疗组为89%,硝酸咪康唑治疗组为82%。两种药物耐受性均良好,未报告有全身反应。接受硝酸硫康唑治疗的8例患者和接受硝酸咪康唑治疗的4例患者报告有与药物相关的皮肤不良反应,主要为短暂瘙痒。